UK markets open in 1 hour 55 minutes

Emergent BioSolutions Inc. (0IGA.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
2.0500-0.0100 (-0.49%)
At close: 04:21PM BST

Emergent BioSolutions Inc.

400 Professional Drive
Suite 400
Gaithersburg, MD 20879
United States
240 631 3200
https://www.emergentbiosolutions.com

Sector(s)
Industry
Full-time employees1,600

Key executives

NameTitlePayExercisedYear born
Mr. Richard S. Lindahl M.B.A.Executive VP, CFO & Treasurer799.38kN/A1964
Ms. Jennifer L. FoxExecutive VP of External Affairs, General Counsel & Corporate Secretary675.74kN/AN/A
Mr. Joseph C. Papa Jr.CEO, President & DirectorN/AN/A1956
Mr. Robert G. BurrowsVice President of Investor RelationsN/AN/AN/A
Ms. Coleen GlessnerExecutive Vice President of Global Quality and Ethics & ComplianceN/AN/AN/A
Michelle PepinSenior VP & Chief Human Resource OfficerN/AN/AN/A
Ms. Stephanie DuatschekSenior VP, Chief Strategy & Transformation OfficerN/AN/AN/A
Dr. Kelly Lyn WarfieldSenior VP of Science & DevelopmentN/AN/AN/A
Mr. Paul A. WilliamsSenior Vice President of Products BusinessN/AN/AN/A
William HartzelSenior Vice President of Manufacturing & BioservicesN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Corporate governance

Emergent BioSolutions Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 10; Board: 2; Shareholder rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.